Researchers at the University of Calgary and the Chinese University of Hong Kong propose that inflammatory bowel disease (IBD) progresses through four temporal and spatial epidemiologic stages as it spreads globally.
Advertisement
At-home administration was safe, effective, and had higher participant satisfaction.
Drs. Peter Richardson and George Wan of Mallinckrodt Pharmaceuticals discussed new data on terlipressin for HRS-AKI.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
The American Society of Nephrology (ASN) will create a Centers of Excellence in Home Dialysis pilot program.
The new blood test is less invasive and more accessible to patients.
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.